How Liquid Biopsies Detect Cancer Before Symptoms

A Blood Draw Instead of a Biopsy

For decades, detecting cancer meant waiting for symptoms, then cutting into tissue to confirm a diagnosis. Liquid biopsies upend that sequence entirely. These simple blood tests scan for microscopic traces that tumors shed into the bloodstream—circulating tumor DNA (ctDNA), aberrant proteins, and other molecular signals—potentially catching cancer years before a patient feels anything wrong.

The concept has moved rapidly from laboratory curiosity to large-scale clinical trials, with several multi-cancer early detection (MCED) tests now being evaluated in tens of thousands of patients worldwide.

What the Blood Reveals

Every cell in the body releases fragments of DNA when it dies—a natural process called apoptosis. These fragments, known as cell-free DNA (cfDNA), drift through the bloodstream and are normally cleared within hours. When a tumor is present, it contributes its own cfDNA carrying telltale mutations or altered methylation patterns.

Liquid biopsies exploit this phenomenon using several complementary approaches:

• Mutation detection: Sequencing blood cfDNA to find cancer-specific genetic mutations using techniques like droplet digital PCR (ddPCR) or next-generation sequencing (NGS).
• Methylation analysis: Examining chemical tags on DNA that regulate gene activity. Methylation patterns differ by tissue type and shift when cells become cancerous, allowing tests to identify not just that cancer exists but where it originated.
• Circulating tumor cells (CTCs): Capturing whole cancer cells that have broken away from a primary tumor and entered the bloodstream.
• Extracellular vesicles: Analyzing tiny membrane-bound packages that tumors release, carrying proteins and RNA that reveal their origin.

From Lab to Clinic: Key Tests

The most advanced MCED test in clinical evaluation is Galleri, developed by GRAIL. In the landmark NHS-Galleri trial—the world's first randomized controlled trial of a multi-cancer blood test—142,000 participants aged 50 to 77 were screened annually over three years. Results published in 2026 showed a four-fold improvement in cancer detection rates compared with standard screening alone, along with a substantial reduction in cancers found through emergency presentation, which typically carry far worse outcomes.

Meanwhile, UCLA researchers unveiled MethylScan in April 2026, a cost-effective approach that filters background DNA to focus on informative methylation fragments. At 98% specificity, MethylScan detected approximately 63% of cancers across all stages—including 55% of early-stage cancers—at an estimated cost of under $20 per sample.

Why Early Detection Matters So Much

Cancer survival rates are dramatically better when the disease is caught early. A stage I diagnosis often means a five-year survival rate above 90%, while stage IV detection may drop that figure below 20% for many cancer types. Liquid biopsies could shift the balance by finding cancers that currently lack any routine screening method—ovarian, pancreatic, liver, and stomach cancers among them.

Critically, these tests also identify the cancer signal of origin—pinpointing which organ is affected so doctors know where to look next, avoiding months of diagnostic uncertainty.

Challenges That Remain

Despite promising results, liquid biopsies face significant hurdles. The fraction of tumor-derived DNA in a blood sample is extraordinarily small—sometimes less than 0.01% of total cfDNA—making accurate detection of rare mutations technically demanding. False positives can trigger unnecessary invasive follow-up procedures and patient anxiety.

No MCED test has yet received full FDA approval. Regulators require evidence not just that tests detect cancer, but that earlier detection actually improves patient outcomes and does not cause net harm through overdiagnosis. Large randomized trials are ongoing to answer these questions definitively.

What Comes Next

More than 300 clinical trials are currently investigating cfDNA-based cancer detection worldwide. As sequencing costs continue to fall and analytical methods improve, liquid biopsies may eventually become as routine as cholesterol screening—a simple annual blood draw that could catch dozens of cancer types at their most treatable stage.